Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−8.272SEK
−309.42 MSEK
1.57 MSEK
44.05 M
About IMMUNOVIA AB
Sector
CEO
Jeff Borcherding
Headquarters
Lund
Website
Founded
2007
FIGI
BBG00JWMYYW7
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0G8X is 1.400 SEK — it has decreased by 4.63% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange IMMUNOVIA AB NPV stocks are traded under the ticker 0G8X.
IMMUNOVIA AB NPV is going to release the next earnings report on Apr 29, 2024. Keep track of upcoming events with our Earnings Calendar.
0G8X stock is 4.86% volatile and has beta coefficient of −0.68. Check out the list of the most volatile stocks — is IMMUNOVIA AB NPV there?
IMMUNOVIA AB NPV revenue for the last quarter amounts to 358.00 K SEK despite the estimated figure of 800.00 K SEK. In the next quarter revenue is expected to reach 2.00 M SEK.
Yes, you can track IMMUNOVIA AB NPV financials in yearly and quarterly reports right on TradingView.
0G8X net income for the last quarter is −49.00 M SEK, while the quarter before that showed −38.56 M SEK of net income which accounts for −27.09% change. Track more IMMUNOVIA AB NPV financial stats to get the full picture.
Today IMMUNOVIA AB NPV has the market capitalization of 93.07 M, it has decreased by 2.35% over the last week.
No, 0G8X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0G8X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOVIA AB NPV stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNOVIA AB NPV technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNOVIA AB NPV stock shows the sell signal. See more of IMMUNOVIA AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.